Merck KGaA (MRK) Given a €115.00 Price Target by Sanford C. Bernstein Analysts

Merck KGaA (FRA:MRK) has been assigned a €115.00 ($136.90) price objective by Sanford C. Bernstein in a research note issued on Wednesday. The firm currently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s price target would indicate a potential upside of 28.26% from the stock’s current price.

MRK has been the subject of several other reports. Oddo Bhf set a €125.00 ($148.81) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Friday, November 10th. JPMorgan Chase & Co. set a €100.00 ($119.05) price objective on Merck KGaA and gave the company a “neutral” rating in a research note on Friday, October 6th. Citigroup set a €123.00 ($146.43) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Monday, September 25th. Goldman Sachs Group set a €105.00 ($125.00) price objective on Merck KGaA and gave the company a “neutral” rating in a research note on Tuesday, September 19th. Finally, UBS Group set a €120.00 ($142.86) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Monday, January 8th. Twelve equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of €107.57 ($128.06).

Merck KGaA (FRA:MRK) traded down €0.46 ($0.55) on Wednesday, reaching €89.66 ($106.74). The company’s stock had a trading volume of 675,971 shares. The stock has a market cap of $11,650.00 and a P/E ratio of 21.00. Merck KGaA has a 12-month low of €87.33 ($103.96) and a 12-month high of €115.00 ($136.90).

TRADEMARK VIOLATION NOTICE: “Merck KGaA (MRK) Given a €115.00 Price Target by Sanford C. Bernstein Analysts” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3145973/merck-kgaa-mrk-given-a-115-00-price-target-by-sanford-c-bernstein-analysts.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.